Metastatic Breast Cancer in Austria
Metastatic Breast Cancer in Austria
Breast cancer is the most common cancer among women worldwide. In Austria, this diagnosis is
 made more than 5000 times a year (STATISTICS AUSTRIA, Austrian Cancer Registry, as of
 24.09.2012). Of these, already 5% to 10% have distant metastases at the time of initial
 diagnosis, and up to 30% of the node-negative tumours and up to 70% of the node-positive
 tumours metastasise at a later date. Metastatic breast cancer has not been systematically
 assessed in Austria to date. This medical registry of the AGMT is thus the first
 Austrian-wide standardised documentation of this disease. The aim of the registry is to
 answer both epidemiological and therapy-specific questions.

 This registry is a prospective and retrospective, multicentre collection of data on patients
 with metastatic breast cancer in Austria. All tumour characteristics, medical histories and
 also treatment sequences are documented in anonymised form.
The present AGMT registry will provide accurate documentation of initial disease progression
 and initial tumour characteristics in patients with metastatic breast cancer in Austria. The
 data collected will include: median age at metastasis, median disease-free survival (DFS)
 between initial diagnosis or first date of absence of disease and occurrence of metastasis,
 histological subtype of the primary tumour, initial TNM stage, grade and receptor status of
 the primary tumour, type and form of adjuvant therapy, pattern of metastasis and metastasis
 site. Characteristics that have a negative prognostic value are expected to be
 overrepresented in the metastatic patient group.

 Also, this AGMT registry is intended to assess the distribution pattern of these metastatic
 stage subtypes in Austria. Additionally, their influence on treatment strategy and outcome is
 to be studied. Furthermore, the frequency and tumour characteristics of breast cancer in male
 patients will be assessed and the influence of gender on treatment strategies identified.

 The AGMT breast cancer registry will conduct an exact analysis of survival data, thereby
 enabling accurate calculations of average survival duration in patients with metastatic
 breast cancer in Austria. Further parameters that reflect the quality or course of
 oncological treatment are the survival rates from the time of metastasis development at 1, 2
 and 5 years after diagnosis.

 This AGMT registry is intended to investigate the response to various therapies in a real
 life population in relation to previous treatments, concomitant diseases and breast cancer
 subtype. The aim is to assess which therapies are used at which time point and on which
 disease subtype they depend.
Inclusion Criteria:

 -  Histological evidence of breast cancer

 -  Histological and/or radiological evidence of metastases

 -  Metastasis within 10 years of registry initiation

 -  Signed informed consent (if a patient has already died at the time of entry, the entry
 can be made without a declaration of consent)

 Exclusion Criteria:

 -  Due to the non-interventional design of the registry there are no specific exclusion
 criteria.